We conclude that several αHS clones that recognize HS epitopes abundant in the tumor vasculature activate ECs as well as transformed cells in vitro, which irrespective of the underlying mechanism, may have important implications for the development of antibody-based targeting of HSPGs in cancer. The gene discussed is AHSG; the disease is cancer.